Tenax Therapeutics Q3 2026 net loss widens 6% to $16.7 million
TENX•Tenax Therapeutics’ third-quarter 2026 net loss widened 6% year over year to $16.7 million. The company had $113.7 million in cash and cash equivalents at September 30, with operations expected to be funded through FY28.
1. Quarterly results and cash
Research and development expenses rose 17% year over year to $12.1 million, while selling, general and administrative expenses fell 12% to $5.7 million. Tenax Therapeutics reported $113.7 million in cash and cash equivalents at September 30, 2026, and said operations were expected to be funded through FY28.
2. Levosimendan trials
Enrollment in LEVEL-2 remains temporarily paused while a protocol amendment targets patients more likely to benefit from levosimendan. The LEVEL trial missed its primary endpoint, and the FDA granted a Type C meeting to discuss levosimendan development.
